Total trials
112
Active
28
Phase 3
5
Total enrollment
114,964
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Additional vaccination against shingles | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 2 | ||
| Amivantamab Intravenous | — | — | — | — | — | 1 | |
| Carboplatin/Pemetrexed | — | — | — | — | — | 1 |
Next readouts
- 2027-07-31
- 2027-09
- 2029-12-31
Top conditions
- Heart Failure9
- Peripheral Arterial Disease7
- Myocardial Infarction4
- Coronary Artery Disease4
- Lung Cancer3
- Aging3
- Coronary Heart Disease3
- Hereditary Hemorrhagic Telangiectasia3
Frequently asked questions about University Hospital, Essen
- How many clinical trials does University Hospital, Essen have on ClinicalTrials.gov?
- University Hospital, Essen is listed as the lead sponsor on 112 clinical trials in ClinicalTrials.gov, 28 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Essen's trials are in Phase 3?
- 5 of University Hospital, Essen's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University Hospital, Essen focus on?
- University Hospital, Essen's most-studied conditions on ClinicalTrials.gov are Heart Failure, Peripheral Arterial Disease, Myocardial Infarction, Coronary Artery Disease, Lung Cancer.
- When are University Hospital, Essen's next clinical trial readouts?
- University Hospital, Essen has 3 upcoming primary-completion readouts tracked here; the soonest is “Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)”, expected around 2027-07-31.